First patient dosed in the SPAGOPIX-01 study
The first patient in the clinical study SPAGOPIX-01 has been successfully dosed with the contrast agent SN132D and completed MRI.The clinical study SPAGOPIX-01 is conducted at the Uppsala University Hospital in Sweden and will include up to 20 patients with with confirmed breast cancer. The primary objective is to evaluate safety of SN132D in patients with confirmed breast cancer. In preclinical studies, SN132D demonstrated good tolerability with a wide safety margin to the doses investigated in SPAGOPIX-01. During the study, the contrast between tumor tissue and healthy tissue on MRI